GlobeNewswire Inc.··Greenwich Lifesciences, Inc.Greenwich LifeSciences Shows Promise for Breast Cancer Prevention at AACR 2026
$GLSI's GLSI-100 immunotherapy demonstrates 70-80% recurrence reduction in Phase III trial data accepted for AACR presentation.
GLSIbreast cancerGLSI-100